Clinical Trials Directory

Trials / Completed

CompletedNCT01641159

Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence

A Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence (BRAC)

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
62 (actual)
Sponsor
University of Cincinnati · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate whether or not buspirone is effective in preventing relapse in cocaine-dependent adults in inpatient/residential treatment who are planning to enter outpatient treatment upon inpatient/residential discharge.

Detailed description

The primary objective is to evaluate the efficacy of buspirone, relative to placebo, in preventing relapse in cocaine-dependent adults in inpatient/residential treatment who are planning to enter outpatient treatment upon inpatient/residential discharge. Secondary objectives include evaluating the impact of buspirone, relative to placebo, on other drug-abuse outcomes and on factors that may mediate buspirone's efficacy as a relapse-prevention treatment.

Conditions

Interventions

TypeNameDescription
DRUGBuspironeStudy participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.
DRUGPlaceboStudy participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.

Timeline

Start date
2012-08-01
Primary completion
2013-06-01
Completion
2013-06-01
First posted
2012-07-16
Last updated
2015-01-07
Results posted
2014-12-17

Locations

6 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01641159. Inclusion in this directory is not an endorsement.